| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9154457 | American Heart Journal | 2005 | 8 Pages |
Abstract
No currently available agents have been shown in a prospective, randomized, clinical trial to improve outcomes in patients with AHF. Thus, the VERITAS program will provide valuable insights into the effect of tezosentan on clinical outcomes in patients with AHF, as well as hemodynamics and clinical symptoms.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
John R. MD, John J.V. MD, Robert C. MD, John G.F. MD, Gadi MD, Guillaume MD, Henry MD, Marco MD, Christopher M. MD, John D. MD, Guillermo MD, PhD, Dirk J. MD, Aline PharmD, Maurizio PhD, Isaac MD, VERITAS Investigators VERITAS Investigators,